Top Page
Adherium Ltd.
(Sydney:ADR)
Adherium Ltd. (ADR) vs. iShares MSCI Australia ETF (EWA)
Adherium Ltd. Business Overview & Revenue Model
Adherium Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 817.24K | 817.24K | 840.98K | 3.19M | 529.00K | 401.00K |
| Gross Profit | 111.37K | 111.37K | 267.70K | 1.69M | -690.00K | -789.00K |
| EBITDA | -12.44M | -12.44M | -11.56M | -11.50M | -12.65M | -13.03M |
| Net Income | -12.68M | -12.68M | -10.22M | -9.86M | -10.04M | -15.04M |
Balance Sheet | ||||||
| Total Assets | 3.52M | 3.52M | 9.89M | 12.68M | 8.53M | 17.04M |
| Cash, Cash Equivalents and Short-Term Investments | 43.26K | 43.26K | 6.20M | 9.08M | 5.28M | 15.18M |
| Total Debt | 3.12M | 3.12M | 93.20K | 44.00K | 85.00K | 0.00 |
| Total Liabilities | 8.28M | 8.28M | 3.41M | 3.47M | 3.00M | 3.00M |
| Stockholders Equity | -4.76M | -4.76M | 6.48M | 9.21M | 5.54M | 14.04M |
Cash Flow | ||||||
| Free Cash Flow | -10.03M | -10.03M | -10.61M | -9.32M | -9.89M | -11.30M |
| Operating Cash Flow | -9.98M | -9.98M | -10.61M | -9.28M | -9.61M | -11.27M |
| Investing Cash Flow | -48.19K | -48.19K | -37.00 | -41.00K | -279.00K | -29.00K |
| Financing Cash Flow | 3.87M | 3.87M | 7.73M | 13.07M | 0.00 | 21.90M |
Adherium Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$29.98M | -4.81 | -58.27% | ― | -7.20% | 28.70% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$27.04M | -2.88 | -103.74% | ― | 14.84% | 39.64% | |
45 Neutral | AU$38.53M | -6.92 | -513.22% | ― | -34.06% | 75.47% | |
39 Underperform | AU$3.12M | -0.91 | -218.52% | ― | -30.80% | -38.95% | |
38 Underperform | AU$5.63M | -3.71 | ― | ― | ― | -55.00% | |
37 Underperform | AU$12.56M | -0.64 | -1476.79% | ― | -2.82% | 32.47% |
Adherium Ltd. Corporate Events
Adherium Limited has announced a partnership with Allergy Partners to deploy its Hailie® Smartinhaler® technology across more than 100 clinics. This collaboration aims to enhance respiratory care on a large scale in the US and potentially beyond, showcasing Adherium’s commitment to improving healthcare outcomes through digital solutions.
Adherium Limited has announced the issuance of 71,005,701 fully paid ordinary shares without disclosure under the Corporations Act 2001. The company has complied with all relevant legal provisions and there is no excluded information that needs to be disclosed, indicating a transparent and compliant operation. This move could potentially enhance Adherium’s market positioning by strengthening its financial base, allowing further development and distribution of its digital health solutions.
Adherium Ltd. has announced the quotation of 71,005,701 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective November 14, 2025. This move is part of the company’s strategy to enhance its capital structure, potentially strengthening its market position in the digital health sector and providing additional resources to support its growth and innovation initiatives.
Adherium Limited announced the successful outcome of its Annual General Meeting, where all resolutions, including a special resolution, were approved by shareholders. This development signifies strong shareholder support and could enhance Adherium’s operational strategies and market positioning, potentially benefiting stakeholders by reinforcing confidence in the company’s governance and future initiatives.
Adherium Ltd. has released a presentation outlining its position in the respiratory care market. The announcement highlights the company’s strategic focus on developing medical devices, while acknowledging the inherent risks and uncertainties in the industry, such as regulatory approvals and market penetration. Stakeholders are advised to consider these factors when evaluating the company’s future performance.
Adherium Ltd. announced a proposed issue of 15 million fully paid ordinary securities, set to be issued on November 25, 2025. This strategic move is likely aimed at raising capital to support the company’s ongoing operations and growth initiatives, potentially enhancing its market position and providing value to its stakeholders.
Adherium Limited has engaged Stralis Capital Partners as its strategic and capital markets advisor to assist with capital management initiatives, including early exercise of options and potential equity capital raising. This partnership aims to enhance Adherium’s capital markets strategy by providing specialist advice and execution capability, with Stralis Capital acting as lead manager for any equity raising activities over the next six months. As compensation, Stralis Capital will receive 15,000,000 fully paid ordinary shares, valued at $75,000, unless shareholder approval necessitates a cash fee. This engagement supports Adherium’s efforts to strengthen its financial positioning and operational capabilities in the digital health sector.
Adherium Limited has successfully raised $2,472,505.205 through the issuance of fully paid ordinary shares following the exercise of 494,501,041 options. This capital raise, conducted without disclosure to investors under specific sections of the Corporations Act, indicates the company’s compliance with relevant legislative provisions and its ongoing commitment to enhancing its financial position. The move is expected to bolster Adherium’s operations and strengthen its market position in the digital health and connected respiratory device industry.
Adherium Limited has announced a change in the director’s interest, specifically involving George Baran, who has increased his indirect interest in the company. This change involves the conversion of options into fully paid ordinary shares and the issuance of bonus options, reflecting a strategic move that could potentially strengthen the company’s market position and stakeholder confidence.
Adherium Ltd. has announced the quotation of a significant number of ordinary fully paid securities on the Australian Securities Exchange (ASX), totaling over 494 million shares. This move is likely to enhance the company’s capital structure and potentially strengthen its market position, offering new opportunities for growth and development in the digital health sector.
Adherium Ltd. has announced the issuance of a significant number of unquoted equity securities, totaling over 494 million options set to expire in November 2026. This strategic move is part of previously announced transactions, potentially impacting the company’s financial structure and market positioning by bolstering its capital resources.
Adherium Limited has issued 62,666,668 fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act 2001. The company confirms compliance with relevant provisions of the Corporations Act and states that no excluded information needs to be disclosed. This announcement reflects Adherium’s ongoing efforts to enhance its financial position and operational capabilities, potentially impacting its market presence and stakeholder interests.
Adherium Ltd has announced a change in the interest of its director, Louis Panaccio, involving the conversion of unlisted options into fully paid ordinary shares and the issuance of bonus options. This change reflects a strategic move in the company’s financial structuring, potentially impacting its market positioning and shareholder value by increasing the director’s stake in the company.
Adherium Ltd. has announced the quotation of 62,666,668 ordinary fully paid securities on the ASX, following the exercise of options and conversion of other convertible securities. This move is expected to bolster the company’s market presence and provide additional capital for its ongoing operations, potentially impacting its industry positioning and offering new opportunities for stakeholders.
Adherium Limited has announced the issuance of a significant number of unquoted equity securities, totaling over 62 million options set to expire in November 2026. This move is part of a previously announced transaction and is not intended to be quoted on the ASX, indicating a strategic decision to bolster the company’s financial positioning and operational capabilities.
Adherium Limited reported a significant 55% increase in device shipments for the quarter ending September 2025, driven by the launch of a new patient education call center and strong partnerships. The company also highlighted groundbreaking results from the iCARE study, demonstrating high adherence rates and validating the Hailie® platform’s value for healthcare systems. These developments are expected to strengthen Adherium’s market position and drive future growth.
Adherium Ltd. has announced the issuance of over one million unquoted equity securities, specifically options set to expire in November 2026. This move is part of previously announced transactions and reflects the company’s ongoing efforts to enhance its financial structure, potentially impacting its market positioning and stakeholder interests.
Adherium Ltd. has announced the quotation of 1,004,372 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from October 21, 2025. This move signifies the company’s ongoing efforts to strengthen its financial position and increase its market presence, potentially benefiting stakeholders by enhancing liquidity and investment opportunities.
Adherium Limited announced a correction to a previous notification regarding the number of issued options due to an administrative error. This update, which affects the company’s unquoted equity securities, highlights the importance of accurate reporting and may influence stakeholders’ perception of the company’s operational diligence.
Adherium Limited has announced an Early Exercise Incentive Offer for its optionholders, allowing them to receive a bonus option for each existing option exercised by November 15, 2025. This initiative aims to streamline the exercise process in line with the company’s cash-flow management and ensure compliance with voting power thresholds, potentially impacting the company’s financial operations and stakeholder interests.
Adherium Ltd. has released a presentation outlining its current position and future prospects in the respiratory care sector. The company acknowledges the inherent risks and uncertainties in its operations, including product development delays and regulatory hurdles, which could impact its market penetration and financial performance. Stakeholders are advised to consider these factors when evaluating the company’s potential growth and success.
Adherium Limited announced an investor webinar to be hosted by CEO Dawn Bitz, aimed at updating stakeholders on the company’s recent activities and future outlook. The webinar signifies Adherium’s commitment to transparency and engagement with investors, potentially impacting its market positioning and stakeholder relations positively.
Adherium Limited’s Hailie Smartinhaler system is revolutionizing the management of chronic respiratory conditions by enhancing patient adherence and self-management, ultimately reducing hospital admissions and healthcare costs. The company is actively expanding its sales in the US and other markets by forming strategic partnerships with major healthcare entities, positioning itself as a leader in digital health solutions for respiratory care.
Adherium Limited announced the issuance of 8,351 fully paid ordinary shares without disclosure to investors under the Corporations Act 2001. The company has complied with relevant legal provisions and confirmed there is no excluded information requiring disclosure, indicating a smooth operational process and adherence to regulatory standards.